Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center

Clinical research site in Baltimore, Maryland · Sidney Kimmel Comprehensive Cancer Center, 401 N Broadway, Baltimore, MD 21231 · (410) 955-5222 · Website

As of July 2026, 89 paid clinical trials are recruiting at Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center in Baltimore, Maryland. Active studies at this site cover conditions such as Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy and B Acute Lymphoblastic Leukemia. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.

Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: July 19, 2026.

Recruiting clinical trials at Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center (89)

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

for Metastatic Castration-resistant Prostate Cancer

34 locations incl. Goodyear

Sponsor: Amgen

Sex: Male·Age: 18+

Code: NCT07213674·Phase 3·Recruiting·Listed Oct 2025

Apply to this trial

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

for Triple Negative Breast Cancer

124 locations incl. Birmingham

Sponsor: Gilead Sciences

Sex: All·Age: 18+

Code: NCT05633654·Phase 3·Recruiting·Listed Dec 2022

Apply to this trial

FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3

for Urinary Bladder Neoplasms

41 locations incl. Tucson

Sponsor: Eli Lilly and Company

Sex: All·Age: 18+

Code: NCT05614739·Phase 1·Recruiting·Listed Nov 2022

Apply to this trial

Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body

for Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion

27 locations incl. Los Angeles

Sponsor: Bayer

Sex: All·Age: All ages

Code: NCT04142437·Recruiting·Listed Oct 2019

Apply to this trial

A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

for Advanced Breast Cancer

37 locations incl. Springdale

Sponsor: Stemline Therapeutics, Inc.

Sex: All·Age: 18+

Code: NCT06638307·Phase 1·Recruiting·Listed Oct 2024

Apply to this trial

Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation

for Metastatic Breast Cancer

31 locations incl. Scottsdale

Sponsor: LeonaBio

Sex: All·Age: 18+

Code: NCT05696626·Phase 3·Recruiting·Listed Jan 2023

Apply to this trial

FOG-001 in Locally Advanced or Metastatic Solid Tumors

for Cancer

30 locations incl. Phoenix

Sponsor: Parabilis Medicines, Inc.

Sex: All·Age: 18+

Code: NCT05919264·Phase 1, Phase 2·Recruiting·Listed Jun 2023

Apply to this trial

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

for Non-Small Cell Lung Cancer

76 locations incl. Phoenix

Sponsor: Summit Therapeutics

Sex: All·Age: 18+

Code: NCT05899608·Phase 3·Recruiting·Listed Jun 2023

Apply to this trial

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

for Pheochromocytoma/Paraganglioma

11 locations incl. Los Angeles

Sponsor: Merck Sharp & Dohme LLC

Sex: All·Age: 12+

Code: NCT04924075·Phase 2·Recruiting·Listed Jun 2021

Apply to this trial

DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors

for Advanced or Metastatic Solid Tumors

13 locations incl. Birmingham

Sponsor: DynamiCure Biotechnology

Sex: All·Age: 18+

Code: NCT05785754·Phase 1·Recruiting·Listed Mar 2023

Apply to this trial

Study of Circular RNA Treatment in Patients With Radiation Induced Xerostomia-1

for Radiation-Induced Xerostomia and Hyposalivation

4 locations incl. Iowa City

Sponsor: RiboX Therapeutics Ltd.

Sex: All·Age: 18+

Code: NCT06714253·Phase 1, Phase 2·Recruiting·Listed Dec 2024

Apply to this trial

A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma

for Multiple Myeloma

5 locations incl. Birmingham

Sponsor: Bristol-Myers Squibb

Sex: All·Age: 18+

Code: NCT05372354·Phase 1, Phase 2·Recruiting·Listed May 2022

Apply to this trial

Music Therapy in Newly Diagnosed Glioblastoma After Chemoradiation Therapy (MELODY-GBM)

for Glioblastoma (GBM)

1 location in Baltimore

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Sex: All·Age: 18+

Code: NCT07375992·Recruiting·Listed Jan 2026

Apply to this trial

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

for Advanced Endometrial Carcinoma

228 locations incl. Virginia

Sponsor: National Cancer Institute (NCI)

Sex: Female·Age: 18+

Code: NCT07198074·Phase 3·Recruiting·Listed Sep 2025

Apply to this trial

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

for Breast Cancer

1105 locations incl. Anchorage

Sponsor: NRG Oncology

Sex: Female·Age: 18 - 60

Code: NCT05879926·Phase 3·Recruiting·Listed May 2023

Apply to this trial

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

for Intracranial Meningioma

456 locations incl. Anchorage

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT02523014·Phase 2·Recruiting·Listed Aug 2015

Apply to this trial

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

for Advanced Esophageal Adenocarcinoma

643 locations incl. Anchorage

Sponsor: Alliance for Clinical Trials in Oncology

Sex: All·Age: 18+

Code: NCT05677490·Phase 3·Recruiting·Listed Jan 2023

Apply to this trial

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

for Head and Neck Squamous Cell Carcinoma

466 locations incl. Anchorage

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: All·Age: 18+

Code: NCT02734537·Phase 2·Recruiting·Listed Apr 2016

Apply to this trial

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

for Chronic Lymphocytic Leukemia

309 locations incl. Tucson

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04269902·Phase 3·Recruiting·Listed Feb 2020

Apply to this trial

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

for Lung Non-Small Cell Carcinoma

640 locations incl. Anchorage

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04267848·Phase 3·Recruiting·Listed Feb 2020

Apply to this trial

Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

for Childhood Extracranial Germ Cell Tumor

387 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: All ages

Code: NCT03067181·Phase 3·Recruiting·Listed Mar 2017

Apply to this trial

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

for Anatomic Stage II Breast Cancer AJCC v8

525 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06058377·Phase 3·Recruiting·Listed Sep 2023

Apply to this trial

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

for Muscle Invasive Bladder Urothelial Carcinoma

449 locations incl. Phoenix

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05987241·Phase 2, Phase 3·Recruiting·Listed Aug 2023

Apply to this trial

Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

for Prostate Cancer (Adenocarcinoma)

359 locations incl. Anchorage

Sponsor: Canadian Cancer Trials Group

Sex: Male·Age: 18+

Code: NCT06592924·Phase 3·Recruiting·Listed Sep 2024

Apply to this trial

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

for Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

382 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 5 - 60

Code: NCT05675410·Phase 3·Recruiting·Listed Jan 2023

Apply to this trial

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

for Acute Myeloid Leukemia

328 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT05564390·Phase 2·Recruiting·Listed Oct 2022

Apply to this trial

Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging

for Biochemically Recurrent Prostate Carcinoma

278 locations incl. Anchorage

Sponsor: ECOG-ACRIN Cancer Research Group

Sex: Male·Age: 18+

Code: NCT04423211·Phase 3·Recruiting·Listed Jun 2020

Apply to this trial

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

for Renal Pelvis and Ureter Urothelial Carcinoma

152 locations incl. Kingman

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT04628767·Phase 2, Phase 3·Recruiting·Listed Nov 2020

Apply to this trial

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

for Oropharyngeal p16INK4a-Negative Squamous Cell Carcinoma

221 locations incl. Tucson

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT01810913·Phase 2, Phase 3·Recruiting·Listed Mar 2013

Apply to this trial

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

for Classic Follicular Lymphoma

250 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT06337318·Phase 3·Recruiting·Listed Mar 2024

Apply to this trial

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

for Prostate Adenocarcinoma

399 locations incl. Birmingham

Sponsor: NRG Oncology

Sex: Male·Age: 18+

Code: NCT05946213·Phase 3·Recruiting·Listed Jul 2023

Apply to this trial

Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

for Acute Myeloid Leukemia

209 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18 - 59

Code: NCT05554406·Phase 2·Recruiting·Listed Sep 2022

Apply to this trial

A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma

for High Grade Osteosarcoma

177 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: Up to 40

Code: NCT05691478·Phase 2, Phase 3·Recruiting·Listed Jan 2023

Apply to this trial

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

for B Acute Lymphoblastic Leukemia

188 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: 365 Days - 25

Code: NCT03959085·Phase 3·Recruiting·Listed May 2019

Apply to this trial

Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer

for Metastatic Colorectal Adenocarcinoma

5 locations incl. Atlanta

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 18+

Code: NCT07147231·Phase 1, Phase 2·Recruiting·Listed Aug 2025

Apply to this trial

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)

for B Acute Lymphoblastic Leukemia

141 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 366 Days - 46

Code: NCT06124157·Phase 2·Recruiting·Listed Nov 2023

Apply to this trial

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

for Acute Myeloid Leukemia

171 locations incl. Birmingham

Sponsor: Children's Oncology Group

Sex: All·Age: Up to 21

Code: NCT04293562·Phase 3·Recruiting·Listed Mar 2020

Apply to this trial

A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis

for Recurrent Langerhans Cell Histiocytosis

103 locations incl. Birmingham

Sponsor: National Cancer Institute (NCI)

Sex: All·Age: 180 Days - 22

Code: NCT05828069·Phase 2·Recruiting·Listed Apr 2023

Apply to this trial

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

for Acute Lymphoblastic Leukemia

156 locations incl. Birmingham

Sponsor: PedAL BCU, LLC

Sex: All·Age: Up to 22

Code: NCT04726241·Phase 1, Phase 2·Recruiting·Listed Jan 2021

Apply to this trial

A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

for Basal Ganglia Germinoma

95 locations incl. Mobile

Sponsor: Children's Oncology Group

Sex: All·Age: 3 - 29

Code: NCT06368817·Phase 2·Recruiting·Listed Apr 2024

Apply to this trial

Showing the 40 most relevant of 89 recruiting trials at this site. Browse all with filters →

More research sites in Baltimore

Johns Hopkins University (185 trials)
Johns Hopkins Hospital (119 trials)
Johns Hopkins University/Sidney Kimmel Cancer Center (64 trials)
University of Maryland (59 trials)
University of Maryland Medical Center (52 trials)
Sinai Hospital of Baltimore (50 trials)
University of Maryland/Greenebaum Cancer Center (47 trials)
Johns Hopkins University School of Medicine (44 trials)
Johns Hopkins (38 trials)
Kennedy Krieger Institute (32 trials)

Explore more

Paid clinical trials in Baltimore, MD · Maryland clinical trials